Clinical Resources
Materials for Providers
Standing Orders for Administering Clesrovimab RSV Preventive Antibody (Enflonsia, by Merck) to Infants
Eligible healthcare professionals may vaccinate infants who meet any of the criteria on this form
Standing Orders for Administering Nirsevimab RSV Preventive Antibody (Beyfortus, by Sanofi) to Infants and High-Risk Young Children
Eligible healthcare professionals may vaccinate infants or high-risk young children who meet any of the criteria on this form
Standing Orders for Administering Respiratory Syncytial Virus Vaccine (RSV) to Adults Age 50 Years and Older
Eligible healthcare professionals may vaccinate adults age 50 years and older who meet any of the criteria on this form
Standing Orders for Administering Pfizer Respiratory Syncytial Virus (RSV) Vaccine (Abrysvo) During Pregnancy
Eligible healthcare professionals may vaccinate pregnant individuals who meet any of the criteria on this form
CDC · FDA · State
ACIP Recommendations
Current Recommendations
Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus–Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2025
MMWR August 28, 2025, 74(32);508–514
Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices— United States, 2024
MMWR August 15, 2024 / 73(32);696-702
Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
MMWR, October 13, 2023, 72(41);1115-1122
Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023
MMWR, August 25, 2023, 72(34); 920–925
Additional Federal Resources
- All current and archived ACIP RSV (Respiratory Syncytial Virus) recommendations
- General Best Practice Guidelines for Immunization
- ACIP RSV (Respiratory Syncytial Virus) recommendations at CDC
- CDC RSV (Respiratory Syncytial Virus) Information for Healthcare Professionals
- RSV Vaccination for Adults 60 Years and Older
Vaccine Information Statements
Immunization Information Statement (IIS) – Respiratory Syncytial Virus (RSV) Preventive Antibody VIS
Updated: September 25, 2023
RSV (Respiratory Syncytial Virus) Vaccine VIS
Updated: January 31, 2025
CDC Recommended Schedules
2025 Child and Adolescent Immunization Schedule
- Page count: 15
- Color
- Size: 8.5 ” x 11″
2025 Adult Immunization Schedule
- Page count: 14
- Color
- Size: 8.5 ” x 11″
FDA Package Inserts & EUAs
RSV: Enflonsia Package Insert
Merck
RSV: Mresvia Package Insert
Moderna
RSV: Beyfortus Package Insert
Sanofi
RSV: Arexvy Package Insert
GSK
RSV: Abrysvo Package Insert
Pfizer
Healthcare Professional Organizations
Vaccine Recommendations
IDSA 2025 Guidelines on the Use of Vaccines for the Prevention of Seasonal COVID-19, Influenza, and RSV Infections in Immunocompromised Patients
To support evidence-based clinical & shared decision-making during the 2025-2026 respiratory tract infection season, IDSA developed rapid guidelines for the use of U.S-licensed vaccine against COVID-19, Influenza, and RSV in adult and pediatric patients who are immunocompromised.
11/18/2025. IDSA Practice Advisory
The Infectious Diseases Society of America (IDSA) develops evidence-based immunization policy and recommendations to prevent infectious diseases across populations. Its recommendations include immunocompromised patients.
AAP Recommendations for the Prevention of RSV Disease in Infants and Children: Policy Statement
The American Academy of Pediatrics (AAP) recommendations for respiratory syncytial virus (RSV) immunization for infants <8 months of age born during or entering their first RSV season and infants and children 8 through 19 months of age at high risk of severe RSV disease and entering their second RSV season.
10/20/2025. Pediatrics (2025) 156 (5): e2025073923.
The American Academy of Pediatrics (AAP) is a leading professional organization that develops evidence-based immunization policy and clinical guidance to protect the health of infants, children, and adolescents. AAP supports pediatric clinicians with education, tools, and advocacy to improve vaccination coverage and safety.
ACOG Practice Advisory — Maternal Respiratory Syncytial Virus Vaccination
This Practice Advisory provides guidance for the use of respiratory syncytial virus (RSV) vaccine during pregnancy for the prevention of severe RSV disease in young infants.
10/2025. ACOG Practice Advisory
The American College of Obstetricians and Gynecologists (ACOG) develops and promotes clinical guidance for safe and effective vaccination of pregnant and reproductive-age patients.
AAFP Fall 2025 Immunization Recommendations
The AAFP has released their fall immunization recommendations, reinforcing a commitment to the health of communities across the country. The AAFP urges all adults, children and families to stay up to date on recommended vaccines to keep themselves and their loved ones healthy.
9/8/2025. AAFP Recommendation Statement.
The AAFP is the largest national association of family physicians and supports evidence-based immunization practices for patients of all ages.
Recommended Schedules
2025 American Academy of Family Practice (AAFP) Adults 19 and Older Immunization Schedule
- Page count: 11
- Color
- Size: 8.5″ x 11″
2025 American Academy of Pediatrics’ (AAP) Recommended Child and Adolescent Immunization Schedule
- Page count: 18
- Color
- Size: 8.5″ x 11″
